-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Recent News from ILCN
-
Recognized Throughout the Cancer Advocacy World for His Red Toque, Angus Pratt Brought Lung Cancer to the Fore in Many Arenas
A real-world example of the progress that has been made in lung cancer care, ILCN editorial group member and contributor Angus Pratt survived more than seven years after his lung cancer diagnosis.
-
Updated Analysis Confirms Adding Pembrolizumab to Chemotherapy Improves Survival in Mesothelioma
Dr. Scott Laurie recently presented data from IND227 that showed the combination improved overall survival by 24% compared with chemotherapy alone.
-
Tarlatamab With Anti-PD-L1 Demonstrates OS Benefit as First-Line Maintenance Therapy After Chemo-IO in ES-SCLC
Lead investigator Dr. Kelly Paulson said the combination demonstrated unprecedented overall survival with a manageable safety profile in this patient population.
-
Challenging the Smoking Status Quo: Making the Case for Non-Anatomical Factors to Refine Lung Cancer Staging
Using the IASLC 9th Edition Staging Database, Dr. Lawson Eng and colleagues evaluated the association between smoking status at diagnosis and OS.
-
IASLC Spotlight: Global Policy and Partnerships Committee
In a Q&A with ILCN, Dr. Gilberto de Lima Lopes, Committee Chair, details how the committee is working to address the most significant global challenges in lung cancer care.
-
IASLC Recommendations Define Core Standards for Molecular Tumor Boards
Lead author, Dr. Mihaela Aldea, discusses how the IASLC’s recently published consensus statement could strengthen new and established molecular tumor boards.
-
Atezolizumab Improves PFS, but Not OS, When Added to Chemotherapy in Older Patients With Advanced NSCLC
Dr. Céline Mascaux said the addition of atezolizumab significantly improved all secondary endpoints independent of PD-L1 expression; however, it was also associated with higher toxicity.
-
Zipalertinib Demonstrates Promising Results for Treatment of Patients With EGFR-Mutated NSCLC After Progression
Dr. Zofia Piotrowska recently shared data that show patients with exon 20 insertions who progress following standard-of-care treatment may benefit from the addition of the TKI.
-
Opening Keynote to Explore Lessons From Neoadjuvant Immunotherapy Trials in Early-Stage NSCLC
Dr. Patrick Forde will open the IASLC | ASCO North America Conference on Lung Cancer with a keynote address highlighting the evolving role of neoadjuvant immunotherapy in lung cancer care.
-
In Brief for December 3, 2025
The US FDA has granted two separate approvals: one to sevabertinib for non-squamous NSCLC and another to tarlatamab-dlle for ES-SCLC.